About us

Founding Metamorphosis-Tx

December 20, 2023. Metamorphosis-Tx was founded as a subsidiary of DCDC-Tx. Metamorphosis is dedicated to develop cancer differentiation therapy. BioDetection Systems (BDS) is co-founder of Metamorphosis.

CALUX-STP technology of BDS complements STAP-STP technology of DCDC-Tx.

This allows new drug development and drug repurposing.

Team

Clinical, cell biology/molecular biology, stem cell biology, preclinical/clinical drug development, IP, legal, business expertise

founder, CSO (Chief Scientific Officer): Anja van de Stolpe

Dr. Anja van de Stolpe is an internist with clinical, translational, preclinical drug repurposing, and entrepreneurial experience. PhD degree in cell and molecular biology at the Hubrecht Institute (Utrecht, The Netherlands), post-doc at Stanford University.
She is an inventor on a large number of patents, including the STP portfolio.
For publications, see Selected Publications  and ResearchGate. For CV details, see LinkedIn.

FOUNDER, COO (CHIEF OPERATING OFFICER): BRAM BROUWER

Chief Operational Officer: Em. Professor Abraham Brouwer, CEO BDS, studied Chemistry in Leiden and obtained a PhD in Medicine; he has over 30 years of experience as licensed toxicologist and held a chair position in Environmental Toxicology and Ecogenomics at VU University Amsterdam. He is the inventor of the CALUX technology. For CV and publications, see LinkedIn and ResearchGate.

FOUNDER, CMO (Chief Medical Officer): Reinier Raymakers

Dr Reinier Raymakers is a clinical hematologist, with focus on hemato-oncology, with extensive translational research (11 PhD theses), and clinical drug development experience.
PhD degree on Autologous Bone Marrow Transplantation for malignancies, post-doc at Roswell Park Cancer Institute (Buffalo, NY) and University Medical Center Leiden (The Netherlands). Clinical staff member at the academic hematology department UMC Radboud and UMC Utrecht. For publications, see Selected Publications and ResearchGate. For CV details, see LinkedIn.

FOUNDER, acting CEO: Frans Bos, PhD Physics, LLM

Extensive managerial experience at Executive level in a broad portfolio of fields

FOUNDER, CFO: YVETTE VAN SCHEPPINGEN


LABORATORY: TJALF DE BOER, PROJECT LEADER

Tjalf de Boer obtained his PhD at the VU Amsterdam, where he also worked as Post Doc, focussing on gene expression and environmental toxicology. He is managing director at BioDetection Systems and Project leader at Metamorphosis Tx. For CV and publications, see LinkedIn and ResearchGate, Google Scholar.

LABORATORY: CLEMENCE BUDIN, PRINCIPLE INVESTIGATOR

Clémence studied Engineering with a major in Biology (Polytech Clermont-Ferrand) and completed her PhD in Toxicology at the Vrije Universiteit Amsterdam. She has experience in the development and application of biotechnologies. For CV and publications, see LinkedIn and ResearchGate, Google Scholar.

Legal adviser: Jan Karel van der Staay, LLM

Former General Counsel. Extensive governance, legal and M&A experience at Board level. For CV details, see LinkedIn.

Advisory board

Metamorphosis Tx has an informal international clinical and scientific advisory board, providing state-of-the-art relevant expertise on demand.